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Abstract
Mast cells are key initiators of allergic, anaphylactic and inflammatory reactions, producing mediators that affect vascular
permeability, angiogenesis and fibrosis. Glucocorticoid pharmacotherapy reduces mast cell number, maturation and
activation but effects at physiological levels are unknown. Within cells, glucocorticoid concentration is modulated by the
11b-hydroxysteroid dehydrogenases (11b-HSDs). Here we show expression and activity of 11b-HSD1, but not 11b-HSD2, in
mouse mast cells with 11b-HSD activity only in the keto-reductase direction, regenerating active glucocorticoids (cortisol,
corticosterone) from inert substrates (cortisone, 11-dehydrocorticosterone). Mast cells from 11b-HSD1-deficient mice show
ultrastructural evidence of increased activation, including piecemeal degranulation and have a reduced threshold for IgG
immune complex-induced mast cell degranulation. Consistent with reduced intracellular glucocorticoid action in mast cells,
levels of carboxypeptidase A3 mRNA, a glucocorticoid-inducible mast cell-specific transcript, are lower in peritoneal cells
from 11b-HSD1-deficient than control mice. These findings suggest that 11b-HSD1-generated glucocorticoids may tonically
restrain mast cell degranulation, potentially influencing allergic, anaphylactic and inflammatory responses.
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Introduction
Mast cells play a central (typically initial) role in inflammatory
and allergic reactions. They guard against bacterial pathogens and
participate in tissue repair by producing mediators that promote
vascular permeability, angiogenesis and fibrosis. Mast cells
accumulate in chronically inflamed tissues in humans and in
mice, and have consistently been observed in high numbers in
human rheumatoid arthritis (reviewed, [1]), in Crohn’s disease
(reviewed, [2]) and in the bronchus of asthmatic patients [3,4].
Mast cells contain preformed tumour necrosis factor (TNF)-a in
granules and can rapidly produce large amounts of both TNF-a
and interleukin (IL)-1 [5] as well as other mediators, including
histamine, eicosanoids (particularly prostaglandin D2) and vascular
endothelial growth factor, which contribute to oedema, inflam-
mation, hyperplasia and neovascularisation.
Glucocorticoids reduce mast cell number, maturation and
activation [6,7,8,9], contributing to the potent anti-allergic and
anti-inflammatory effects of these steroids. Blood glucocorticoid
levels depend upon activity of the hypothalamic-pituitary-adrenal
axis. However, intracellular glucocorticoid concentrations can
differ greatly from blood levels due to the action of 11b-
hydroxysteroid dehydrogenase (11b-HSD), an enzyme that
interconverts active glucocorticoids (cortisol in humans, cortico-
sterone in rodents) and intrinsically inert 11-keto metabolites
(cortisone, 11-dehydrocorticosterone). Two isozymes exist; 11b-
HSD1 and 11b-HSD2. Whereas 11b-HSD2 inactivates glucocor-
ticoids and is largely restricted to mineralocorticoid target tissues
in the adult, 11b-HSD1 catalyses the opposite reaction in vivo,
predominantly reactivating glucocorticoids by converting inert 11-
keto-glucocorticoids into active forms and shows a more
widespread distribution [10]. Mice homozygous for a targeted
disruption of the Hsd11b1 gene that encodes 11b-HSD1
(Hsd11b12/2 mice) have normal blood glucocorticoid levels on
the C57BL/6J strain background [11] yet have a phenotype
consistent with intracellular glucocorticoid deficiency (reviewed,
[12]). Thus, they exhibit more severe acute inflammation in
models of myocardial infarction, arthritis, sterile peritonitis and
carageenan-induced pleurisy [13,14]}, suggesting 11b-HSD1
normally exerts a restraining influence upon the early inflamma-
tory response. In vivo, 11b-HSD1 expression is rapidly and
markedly increased at sites of inflammation, including in
peritoneal immune cells during sterile peritonitis [15], in colitis
[16,17] and in the arthritic joint [18]. 11b-HSD1 is expressed in
macrophages [15,19] where it performs an anti-inflammatory
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function, accelerating acquisition of macrophage phagocytic
competence [15]). Expression has also been shown in dendritic
cells [20], neutrophils [21] and lymphocytes [22], though its role in
these cells remains uncharacterised. Here, we describe expression
and activity of 11b-HSD1 in mast cells, classical glucocorticoid-
targets in allergic and anaphylactic reactions, and demonstrate a
restraining influence of 11b-HSD1 on mast cell degranulation.
Materials and Methods
Ethics Statement
All animal experimentation was conducted in strict accord with
accepted standards of humane animal care under the auspices of
the Animal (Scientific Procedures) Act UK 1986 following prior
approval by the local University of Edinburgh ethical committee.
Animals
Mice homozygous for a targeted disruption of the Hsd11b1 gene
on a C57BL/6J background (.8 backcrosses) have been described
[15]. Control age-matched C57BL/6J (Hsd11b1+/+) mice were
bred in-house. Mice were housed in groups of 2–5 per cage under
controlled conditions (12 h-light/dark cycle, 21uC) with ad libitum
access to water and standard rodent chow.
Generation of Anti-glucose 6-phosphate Isomerase IgG
Immune Complexes
Arthritogenic K/BxN serum containing anti-glucose 6-phos-
phate isomerase (GPI) IgG immune complexes was generated in
house from arthritic K/BxN mice (expressing both the KRN T
cell receptor transgene and the MHC class II molecule Ag7) as
described [14].
Bone Marrow-derived (BMD) Mast Cell and Macrophage
Cultures
BMD-mast cells and BMD-macrophages were cultured as
previously described [15,23] from 10 week old male C57BL/6
mice. Briefly, BMD-mast cells were obtained following 21d
incubation in DMEM medium supplemented with recombinant
mouse IL-3 (1 ng/ml) and SCF (50 ng/ml) (PeproTech EC Ltd,
London, UK). Mast cell purity was confirmed by immunofluores-
cent staining with tryptase (mMCP-6) antibody and this protocol
routinely gives .98% pure mast cells [24]. BMD-macrophages
were obtained following 7d incubation in DMEM/F12 (Invitro-
gen, Paisley, UK) supplemented with 10% FCS, 500 U/ml
penicillin, 500 U/ml streptomycin and 10% conditioned medium
from murine fibrosarcoma cell (L929) cultures.
Assay of 11b-HSD1 Activity
11b-HSD1 activity (dehydrogenase and reductase) was
measured as previously described [15]. Briefly, 200 nM corti-
costerone or 11-dehydrocorticosterone, containing trace
amounts of [3H]-corticosterone (specific activity ,80 Ci/mmol;
Amersham Pharmacia Biotech, Buckingham, UK) or [3H]-11-
dehydrocorticosterone (made as previously described; [15]), was
added to cell culture medium. At various times steroids were
extracted in triplicate and analysed either by thin layer
chromatography or by high performance liquid chromatography
as previously described [15].
RNA Extraction and Analysis
Total RNA was extracted from cells as previously described
[15]. For RT-PCR, 1 mg RNA was reverse transcribed and
subjected to PCR as described [15]. 11b-HSD2 primers: forward,
59-CTGAAGCTGCTGCAGATTGGAT-39 and reverse, 59-
GAGCAGCCAGGCTTGATAATG-39. 11b-HSD1 PCR reac-
tions all used a common reverse primer, 868P 59- AGGATC-
CARAGCAAACTTGCTTGCA-39, complementary to exon 6,
and one of the following forward primers: 869P 59-
AAAGCTTGTCACWGGGGCCAGCAAA-39, in exon 3, com-
mon to all 11b-HSD1 transcripts; ex2, 59-
GTCCCTGTTTGATGGCAG-39, in exon 2, common to P1
and P2 transcripts; P1, 59-GGAGCCGCACTTATCTGAA-39,
specific for transcripts arising from P1; P2, 59-GGAGGTTGTA-
GAAAGCTCTG-39, specific to transcripts arising from P2; P3,
59-GTATGGAAAGCAAGACAAGG-39, specific for transcripts
arising from P3 (in the intron between exons 2 and 3). Real-time
PCR was carried out on a LightCycler 480, according to the
manufacturer’s instructions. Mastermix and primer-probe sets for
18S RNA (4331182), TATA-Binding Protein (TBP)
(Mm00446973_m1), carboxypeptidase A3 (Mm00483940) and
annexin 1 (Mm00440225_m1) cDNAs were purchased from
Applied Biosystems (Warrington, UK). Neither internal standard
differed between genotypes and accordingly TBP was used as the
internal standard.
Analysis of Peritoneal Mast Cells
For analysis of peritoneal mast cells, 8–12 week old male and
female mice were used. Following peritoneal lavage, enriched
peritoneal mast cells were prepared from freshly isolated
peritoneal cells, positively selected for CD117+ mast cells using
magnetic beads (Miltenyi Biotec, Surrey UK) according to the
manufacturer’s instructions. Generally, around 50% pure mast cell
populations were achieved based on histochemical staining of
cytocentrifuge preparations or flow cytometry analysis. Mast cell
degranulation was determined by measuring the release of b-
hexosaminidase as described [25]. Briefly, peritoneal cells were
incubated in triplicate for 15 min at 37uC in Tyrode’s Buffer and
were untreated or treated with 10 mM ionomycin or diluted K/
BxN serum. Following incubation, cells were collected by
centrifugation. Aliquots (in triplicate) of the supernatant were
transferred to a 96-well plate. The remaining supernatant was
carefully removed and cell pellets solubilized in Tyrode’s buffer
with the addition of 0.5% Triton X-100. Aliquots (in triplicate) of
the solubilized pellet were also transferred to a 96-well plate. Next,
b-hexosaminidase substrate (1 p-nitrophenyl-N-acetyl-b-D-glucos-
amine) was added to each well and incubated for 40 min at 37uC.
Reactions were stopped by the addition of glycine and absorbance
was measured at 405 nm. Total mast cell b-hexosaminidase was
measured in untreated cells solubilized by the addition of Triton
X-100. For each sample, degranulation was calculated as A405
supernatant/(A405 supernatant+A405 pellet). The mean of the
untreated samples in each group was arbitrarily set to 100, and all
other values expressed relative to this. Net degranulation was
calculated as the difference between treated and untreated samples
(and is thus % degranulation above levels in untreated cells). In
preliminary experiments, no differences in mast cell number or
level of degranulation were observed between the sexes of either
genotype, therefore total peritoneal cells from both sexes were
used.
Flow Cytometry
Anti-mouse CD117 (c-Kit)-phycoerythrin (PE) or -allophyco-
cyanin (APC), anti-mouse FccR-PerCP Cy5.5, FceR-PE and IgG
controls (eBiosciences, Middlesex, UK) were added to peritoneal
cells at concentrations recommend by the supplier and incubated
on ice for 30 min in the dark. 11b-HSD1 sheep-derived antibody,
generated in-house [26], was used in combination with Donkey
11b-HSD1 in Mast Cells
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Figure 1. Mast cells express 11b-HSD1. (A) 11b-HSD1 reductase (conversion of 11-dehydrocorticosterone to corticosterone; Solid lines/black
squares) and dehydrogenase (conversion of corticosterone to 11-dehydrocorticosterone; dashed lines/open squares) activities in BMD-MC (.98%
pure, assessed by tryptase staining as previously described [24]) are expressed as % conversion of 200 nM substrate by 26106 cells, over time (h).
Values are mean6 SEM of 3 independent assays carried out on pooled BMD-MC. (B) BMD-MC express 11b-HSD1 mRNA (upper panel; 469 bp RT-PCR
product with primers 868P and 869P) but not 11b-HSD2 mRNA (lower panel; 400 bp RT-PCR product). Lanes 5 and 6 show RT-PCR products from 2
independent Hsd11b1+/+ BMD-MC RNA samples. Positive controls (+) comprised liver mRNA (lane 4, upper panel) or kidney mRNA (lane 4, lower
panel). Negative controls contained BMD-MC RNA but no reverse transcriptase (2, lane 3) or water (lane 2). Lane 1 contains a 100 bp ladder
11b-HSD1 in Mast Cells
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anti-sheep secondary antibody (Alexa Fluor 488) (Invitrogen,
Paisley, UK). During the staining procedure, cells were treated
with a fixation and permeabilization kit (Fix and Perm, Invitrogen,
Paisley, UK) according to the manufacturer’s instructions, in order
to allow for intracellular staining with the 11b-HSD1 antibody.
Fluorescence was determined by FACScalibur using Cellquest
(Becton Dickinson UK Ltd, Oxford, UK) and analysed using
FlowJo software (Treestar, Ashland, Oregon, USA).
Transmission Electron Microscopy
Samples were fixed in 3% glutaraldehyde in 0.1M sodium
cacodylate buffer, pH 7.3, for 2 h then washed 3 times (each for
10 min) in 0.1M sodium cacodylate. Specimens were post-fixed in
1% osmium tetroxide in 0.1M sodium cacodylate for 45 min,
washed again (as above) then dehydrated in 50%, 70%, 90% and
100% acetone (10 min each), then twice further in 100% acetone.
Samples were embedded in Araldite resin and 1 mm thick sections
cut on a Reichert OMU4 ultramicrotome (Leica Microsystems
UK Ltd, Milton Keynes, UK), stained with toluidine blue and
viewed in a light microscope to select suitable areas for
investigation. Ultrathin (60 nm thick) sections were cut from
selected areas, stained in uranyl acetate and lead citrate then
viewed in a Phillips CM120 Transmission electron microscope
(FEI UK Ltd, Cambridge, UK). Images were captured using a
Gatan Orius CCD camera (Gatan UK, Oxon, UK).
Statistics
Student’s t-test was used for comparisons between genotypes.
Significance was set at p,0.05. Values are means 6 SEM.
(Promega, Southampton, UK). (C) Hsd11b12/2 BMD-MC lack 11b-HSD1 activity. 11b-HSD1 reductase activity was measured in Hsd11b1+/+ (+/+) and
Hsd11b12/2 (2/2) BMD-MC. Data are expressed as % conversion of 200 nM 11-dehydrocorticosterone to corticosterone by 26106 cells in a 10 h
assay. Values are means of triplicate assays performed on pooled BMD-MC. ND, not detected. (D) Mast cells transcribe Hsd11b1 from the P1 promoter,
whereas macrophages use the P2 promoter. Upper panel; RT-PCR products from 3 independent BMD-MC RNA samples showing the 627 bp RT-PCR
product from P1 transcripts of 11b-HSD1 (lanes 4–6), but not P2 (predicted product of 647 bp, lanes 7–9) or P3 (predicted product of 542 bp, lanes
10–12). Kidney RNA confirmed transcription from P3 (not shown). Total 11b-HSD1 mRNA was detected using ex2 and 868P primers common to all
transcripts (lanes 13–15, 587 bp product). Lower panel; RT-PCR products from BMD macrophage RNA showing the 647 bp RT-PCR P2 product (lane
3), but not the P1 (lane 2) or P3 products (lane 4). Total 11b-HSD1 mRNA (T) was detected using 868P and 869P primers, common to all transcripts
(lanes 5, 6; 469 bp product). Lane 1 contains a 1 kb ladder (Invitrogen, Paisley, UK). Lanes marked (0) contain water only and lanes marked (2) show
RT-PCR reactions from which the RT was omitted. (E) Flow cytometric staining revealed 11b-HSD1+CD117+ peritoneal cells. Freshly isolated peritoneal
cells (,56105 cells per sample) from male C57BL/6 mice were stained with 11b-HSD1 and CD117+ antibodies. Total peritoneal cells were first gated
according to side scatter (SSC) and forward scatter (FSC) (i), then cells with high granularity, where mast cells lie (see Figure S1), were assessed for
11b-HSD1 and CD117 staining (ii–vii). Controls included; (ii) high SSC cells alone, (iii) sheep IgG control for 11b-HSD1 antibody, (iv) 11b-HSD1 antibody
only, (v) isotype control for CD117 and (vi) CD117 antibody only. Panel (vii) shows cells double stained with 11b-HSD1 and CD117 antibodies.
doi:10.1371/journal.pone.0054640.g001
Figure 2. More mast cells in the peritoneum of Hsd11b12/2mice. (A) Representative dot plots of freshly isolated peritoneal cells (56105) from
Hsd11b1+/+ (left) and Hsd11b12/2 (middle) mice stained for CD117 (a mast cell marker) or isotype control (right) and subject to flow cytometry. (B)
Peritoneal cells from Hsd11b12/2 mice (2/2, white bars) have more CD117+ cells than Hsd11b1+/+ (+/+, black bars), expressed as percentage of total
cells (total cell number; Hsd11b1+/+, 3.860.56106 vs Hsd11b12/2, 3.760.56106, p.0.05). (C) CD117+ cells from Hsd11b12/2 mice have higher mean
fluorescence intensity (MFI) compared to Hsd11b1+/+ mice (black bars). Data are mean 6 SEM, n = 8, *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0054640.g002
11b-HSD1 in Mast Cells
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Results
11b-HSD1 is Expressed in Mast Cells
With 11-dehydrocorticosterone as substrate, BMD-mast cells
show 11b-keto-reductase activity (Figure 1A; 16.961.1 pmol corti-
costerone/h/106 cells). In contrast, BMD-mast cells show negligible
11b-dehydrogenase activity with corticosterone as substrate
(Figure 1A) showing the absence of 11b-HSD2 and indicating 11b-
HSD1 is a predominant 11b-reductase in mast cells. Consistent with
this, 11b-HSD1 mRNA is present and 11b-HSD2 mRNA absent in
mast cells (Figure 1B). BMD-mast cells from 11b-HSD1-deficient
mice lack 11b-HSD1 activity (Figure 1C), confirming the activity is
due to 11b-HSD1. 11b-HSD1 mRNA is transcribed from 3 distinct
promoters [27,28]. Transcription of theHsd11b1 gene in BMD-mast
cells initiates at the upstream P1 promoter, with little or no
transcription from the downstream P2 and P3 promoters
(Figure 1D). Importantly, this contrasts with BMD-macrophages
which exploit the P2 promoter (Figure 1D), suggesting that these P1-
initiated transcripts are in mast cells and not in contaminating
macrophages.CD117orc-Kit, isamarker formaturemastcells.Flow
cytometric staining of lavaged peritoneal cells (of which ,3% are
mastcells; seeFigureS1 fordefinitionof theCD117+population)with
11b-HSD1 antibody demonstrates immunoreactive protein in
CD117+ cells (Figure 1E), confirming 11b-HSD1 expression in mast
cells in vivo as well as in vitro.
11b-HSD1-deficiency Alters Peritoneal Mast Cell Number
and Phenotype
Mast cell number and phenotype are both influenced by
glucocorticoids [6,7,8,9]. To address whether either are affected
by 11b-HSD1-deficiency, peritoneal mast cells from naive
Hsd11b12/2 mice were subject to flow cytometry. More
CD117+ cells are present in the peritoneum of naı¨ve Hsd11b12/
2 mice than controls (Figure 2A, B) and CD117+ cells from
Hsd11b12/2 mice have higher mean fluorescence intensity
(Figure 2C) suggesting increased surface expression of CD117 on
peritoneal mast cells of Hsd11b12/2 mice. However, the
proportion of CD117+ cells also positive for FceR and FccR mast
cell markers is the same in both genotypes (96.860.4% of
Hsd11b1+/+ and 96.960.9% of Hsd11b12/2 CD117+ cells express
both FceR and FccR markers) with no difference in mean
fluorescence intensity of these receptors between genotypes (FceR-
PE mean fluorescence intensity; Hsd11b1+/+31.260.5 vs
Hsd11b12/2, 28.362.0 and FccR-PerCP Cy5.5 mean fluores-
cence intensity; Hsd11b1+/+, 51.562.0 vs Hsd11b12/2, 53.960.5).
To determine whether mast cell contents are affected by 11b-
HSD1 deficiency, key glucocorticoid-regulated transcripts were
examined. Levels of mRNA encoding carboxypeptidase A3,
Figure 3. Decreased levels of glucocorticoid-sensitive tran-
scripts in peritoneal cells from Hsd11b12/2 mice. Real-time PCR
measurement of (A) Carboxypeptidase A3 and (B) annexin 1 mRNA
levels in total peritoneal cells from naı¨ve male Hsd11b12/2 (2/2; white
bars) or Hsd11b1+/+ (+/+; black bars) mice. Data are mean 6 SEM; n = 8,
*p,0.05, **p,0.01. CPA; carboxypeptidase A3.
doi:10.1371/journal.pone.0054640.g003
Figure 4. Ultrastructural analysis suggests piecemeal degran-
ulation in Hsd11b12/2 mast cells. (A) Representative EM images
showing peritoneal mast cells from Hsd11b12/2 (2/2) and Hsd11b1+/+
(+/+) mice. Closed arrowheads indicate dark (dense) granules and open
arrowheads indicate lighter (less dense) granules. The lighter granules
are suggestive of piecemeal degranulation in Hsd11b12/2 mice. MC;
mast cell, G; granule, N; nucleus. (B) Peritoneal mast cells from
Hsd11b12/2 (2/2) mice have fewer electron dense granules (black
bars) and more ‘‘lighter’’ granules (white bars) compared to mast cells
from Hsd11b1+/+ (+/+) mice. At least 40 individual mast cells from a
pooled sample from each genotype were scored by 2 independent
observers, blind to genotype. Data are expressed as mean 6 SEM;
**p,0.01.
doi:10.1371/journal.pone.0054640.g004
11b-HSD1 in Mast Cells
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generally considered a mast cell-specific product [29,30] that is
glucocorticoid-inducible [8], are lower in peritoneal cells from
Hsd11b12/2 mice, compared to controls despite increased
peritoneal mast cell number, consistent with reduced intracellular
glucocorticoid action in 11b-HSD1-deficient mast cells (Figure 3A).
Moreover, although not mast cell-specific, levels of annexin I
mRNA (formerly called lipocortin), a classic glucocorticoid-
inducible gene [31], are also reduced in peritoneal cells from
Hsd11b12/2 mice (Figure 3B).
To investigate whether the characteristic granule morphology of
mast cells is affected by 11b-HSD1-deficiency, transmission
electron microscopy was carried out on an enriched population
of peritoneal mast cells (,50% mast cells). Total granule number
per cell did not differ between genotypes Hsd11b1+/+55.6614.7
(n = 41) vs Hsd11b12/261.6619.4 (n = 49). However, whereas
mast cells from control mice predominantly contain homoge-
neously electron dense granules (Figure 4A), those from
Hsd11b12/2 mice are more heterogeneous and contain a greater
proportion of lighter granules (Figure 4A, B) as well as enlarged
partially filled and empty vesicles, characteristic of piecemeal
degranulation [32], a slower form of mast cell degranulation than
anaphylactic degranulation, that has been associated with
persistent inflammation [32].
11ß-HSD1 Deficiency Reduces the Activation Threshold
of Peritoneal Mast Cells
To determine whether 11b-HSD1-deficiency functionally alters
mast cells as suggested by the granule morphology, we measured
mast cell degranulation by assaying b-hexosaminidase release.
Maximal degranulation induced by 10 mM ionomycin was similar
in peritoneal cells from Hsd11b12/2 and control mice (Figure 5A).
A similar maximal level of degranulation was observed following
15 min incubation with a 1:2 dilution of K/BxN serum
(containing anti-glucose 6-phosphate isomerase IgG immune
complexes, a potent trigger of mast cell degranulation) into culture
medium (Figure 5B). However, 15 min incubation with a lower
concentration of K/BxN serum (diluted 1:8 in medium) induced
significantly more degranulation of peritoneal mast cells from
Hsd11b12/2 than control mice (Figure 5B). Furthermore, when an
enriched population of peritoneal CD117+ cells (,50% mast cells)
was incubated for 21 h with K/BxN serum (diluted 1:8 in
medium), microscopic examination revealed extensive degranula-
tion of 11b-HSD1-deficient mast cells, whereas controls showed
little or no degranulation (Figure 5C). 11b-HSD1-deficiency
therefore lowers the threshold for degranulation of resident mast
cells following IgG immune complex activation.
Discussion
Pharmacological levels of glucocorticoids have potent effects on
mast cells, but effects of endogenous glucocorticoids at physiolog-
ical levels are unknown. Mast cells from Hsd11b12/2 mice have a
phenotype consistent with relative glucocorticoid deficiency,
including reduced expression of glucocorticoid-sensitive mast
cell-specific carboxypeptidase A3, suggesting 11b-HSD1-mediated
glucocorticoid amplification tonically suppresses mast cell respons-
es.
11b-HSD1 is expressed in both BMD- and in peritoneal mast
cells. At around 10–20 pmol/h/106 cells, the level of keto-
reductase activity in BMD-mast cells is considerably higher than
that reported for T lymphocytes (,0.1 pmol/h/106 cells; [22])
and comparable with levels in immature BMD-dendritic cells
(7 pmol/h/106 cells; [20]) and BMD-macrophages (12 pmol/h/
106 cells). Thus, the measured activity is likely to be due to mast
cells and not to contamination with macrophages or another cell
type expressing 11b-HSD1, present at ,2% of the population.
This is supported by the use of the P1 promoter in mast cells,
which contrasts with most other tissues and cell types, including
macrophages, that use the P2 promoter and suggests a distinct
regulation in mast cells.
Whilst the maximum response to degranulating stimuli was
similar in mast cells from Hsd11b12/2 and control mice
(suggesting Hsd11b12/2 mice have normal levels of b-hexosamin-
idase in stored granules), 11b-HSD1-deficient cells were sensitive
to a low dose of K/BxN serum that was ineffective in control cells,
suggesting that it is the threshold for activation that is reduced,
rather than the total number of stored granules, which was
unchanged in Hsd11b12/2 mice. Ultrastructural analysis of
peritoneal mast cells supported this ‘‘trigger-happy’’ phenotype
of Hsd11b12/2 mast cells and indicated piecemeal degranulation,
a form of non-anaphylactic granule release observed in mast cells
in situ, possibly representing up-regulated constitutive secretion
[32]. This increased sensitivity is likely to reflect a difference in
differentiation, maturation or activation of mast cells, as it is
preserved in the absence of 11b-HSD1 substrate, ex vivo. Density of
Figure 5. Hsd11b12/2 peritoneal mast cells are hyper-respon-
sive to degranulation induced by K/BxN serum. Release of b-
hexosaminidase from peritoneal cells (26106) was measured following
15 min incubation with either (A) 10 mM ionomycin or (B) K/BxN serum
(diluted 1:8 or 1:2 in Tyrode’s buffer). Black bars, Hsd11b1+/+; white bars,
Hsd11b12/2. Data are net degranulation in treated cells above levels
measured in untreated cells (cells only are set to zero; see methods for
details), and are mean 6 SEM; n = 12213, *p,0.05. (C) Representative
micrographs (captured at 406 magnification) of enriched peritoneal
CD117+ cells from Hsd11b1+/+ (+/+, left panels) or Hsd11b12/2 mice (2/
2, right panels) following 21 h incubation with buffer (top panels) or K/
BxN serum (1:8 dilution) (lower panels). Arrowheads indicate degran-
ulated mast cells.
doi:10.1371/journal.pone.0054640.g005
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FccR, key for IgG-mediated signalling, is normal on 11b-HSD1-
deficient mast cells, though it is possible that the threshold for
FccR activation and signalling is reduced. Mast cell number was
increased by ,34% in the peritoneum of Hsd11b12/2 mice. Mast
cell number is reduced by pharmacological glucocorticoid
treatment in vivo, though whether normal physiological glucocor-
ticoid concentrations have a similar effect in vivo has not been
reported. However, given that Hsd11b12/2 mice have normal
plasma corticosterone levels on this genetic background [33] and
we have previously shown normal responses of Hsd11b12/2
immune cells to exogenous corticosterone [15], the increase in the
number of mast cells in the peritoneum of Hsd11b12/2 mice
suggests that 11b-HSD1-mediated regeneration of endogenous
intracellular glucocorticoids limits proliferation of at least some
mast cell populations. In this respect, it is interesting that
activation products of mast cells are chemoattractants for their
progenitors [34,35], suggesting that the basal activation observed
in Hsd11b12/2 mast cells may underlie the increase in peritoneal
mast cell number.
Immune activation is a potent stimulus to the hypothalamic-
pituitary-adrenal (HPA) axis and removal of endogenous gluco-
corticoids or blockade of their actions exacerbates immune and
inflammatory disease in humans and in animal models (reviewed,
[36]). Our data suggest that by providing a ‘‘brake’’ to
spontaneous mast cell degranulation, 11b-HSD1-mediated ampli-
fication of endogenous glucocorticoid action within mast cells may
influence allergic and anaphylactic reactions, in which mast cells
are central, and for which glucocorticoid phamacotherapy remains
a highly effective treatment. Experimental testing of this hypoth-
esis in appropriate in vivo models of anaphylaxis and allergy will be
important in the future. These will be important considerations in
the clinical introduction of selective 11b-HSD1 inhibitors for
treatment of metabolic disease, a side-effect of which could be
mast cell hyper-responsiveness.
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a MACS magnet. (A) Using flow cytometry separate populations;
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assessed for mast cells using side scatter (SSC), forward scatter
(FSC) and staining with CD117 antibody. Panels (i, iii, v) illustrate
the gate for high SSC/CD117+ cells, while panels (ii, iv, vi)
illustrate where the high SSC/CD117+ cells (black) are positioned
against all cells in the sample (grey). This gate was then used to
select for mast cells in all experiments. (B) Mast cells were
confirmed by staining the CD117+ enriched-high SSC/CD117+
population of cells (A (iii) top right gate) with Fc Gamma receptor
(Fc Gamma R) and Fc Epsilon receptor (Fc Epsilon R) (markers of
mast cells) antibodies (iii). Panel (i) shows single stain control for
CD117 only, in the high SSC/CD117+ population of cells,
negative for Fc Gamma R and Fc Epsilon R staining.
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